Linked Life Data

20535115

Source:http://linkedlifedata.com/resource/pubmed/id/20535115

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7
pubmed:dateCreated
2010-7-5
pubmed:abstractText
Multiple trials over the past several years have examined indications for angiotensin receptor blockers (ARBs) in the treatment of left ventricular (LV) dysfunction, both acutely after myocardial infarction and in chronic heart failure (CHF). However, the effects of telmisartan, an ARB in rats with CHF after experimental autoimmune myocarditis (EAM) have not yet been analyzed. CHF was elicited in Lewis rats by immunization with cardiac myosin, and 28 days after immunization, the surviving Lewis rats were divided into two groups and treated with either telmisartan (10 mg kg(-1) day(-1)) or vehicle. After 4 weeks of treatment, we analyzed the effects of telmisartan on cardiac function, proinflammatory cytokines and cardiac remodeling in EAM rats. Myocardial functional parameters measured by hemodynamic and echocardiographic studies were significantly improved by telmisartan treatment in rats with CHF compared with those of vehicle-treated rats with CHF. Telmisartan significantly reduced levels of cardiac fibrosis, hypertrophy and its marker molecules (LV mRNA expressions of transforming growth factor beta 1, collagen I and III, and atrial natriuretic peptide), and peroxisome proliferator-activated receptor--gamma protein expression compared with those of vehicle-treated rats. CHF-induced increases in myocardial mRNA expressions of proinflammatory cytokines, (interleukin (IL)-6, IL-1beta), monocyte chemoattractant protein-1 and matrix metalloproteinases (MMP-2 and -9) were also suppressed by the treatment with telmisartan. Moreover, the plasma level of angiotensin-II was significantly elevated in telmisartan-treated rats. Our results indicate that telmisartan treatment significantly improved LV function and ameliorated the progression of cardiac remodeling in rats with CHF after EAM.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
1348-4214
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
33
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
695-702
pubmed:meshHeading
pubmed-meshheading:20535115-Angiotensin II Type 1 Receptor Blockers, pubmed-meshheading:20535115-Animals, pubmed-meshheading:20535115-Autoimmune Diseases, pubmed-meshheading:20535115-Benzimidazoles, pubmed-meshheading:20535115-Benzoates, pubmed-meshheading:20535115-Cardiomyopathy, Dilated, pubmed-meshheading:20535115-Chronic Disease, pubmed-meshheading:20535115-Cytokines, pubmed-meshheading:20535115-Fibrosis, pubmed-meshheading:20535115-Heart Failure, pubmed-meshheading:20535115-Male, pubmed-meshheading:20535115-Matrix Metalloproteinase 2, pubmed-meshheading:20535115-Matrix Metalloproteinase 9, pubmed-meshheading:20535115-Myocarditis, pubmed-meshheading:20535115-Myocardium, pubmed-meshheading:20535115-Rats, pubmed-meshheading:20535115-Rats, Inbred Lew, pubmed-meshheading:20535115-Ventricular Remodeling
pubmed:year
2010
pubmed:articleTitle
Telmisartan, an angiotensin-II receptor blocker ameliorates cardiac remodeling in rats with dilated cardiomyopathy.
pubmed:affiliation
Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences, Niigata, Japan.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't